Lupus Nephritis Therapeutics - Pipeline Assessment and Market Forecast to 2017

March 8, 2011 - PRLog -- GlobalData estimated that the lupus nephritis market was worth $108m in 2010. The major reason for the limited market revenues was the lack of approved drugs for the treatment of lupus nephritis. Immunosuppressants and corticosteroids are some of the off-label products currently used by lupus nephritis patients. The modest growth forecast is primarily attributed to a weak pipeline landscape. Low prescription rates and low treatment seeking rates continue to pose significant challenges for prospective market entrants, and the market landscape in future is expected to remain static without any significant dynamism. Overall, between 2010 and 2017, the lupus nephritis market is expected to grow at a CAGR (Compound Annual Growth Rate) of 5.70%, to reach $159m by 2017

GlobalData found that the pipeline of the lupus nephritis market is weak, as there are just eight products in different stages of development. There is no promising drug at present. Orencia (Abatacept) was considered a promising drug in Phase III stage of development, but in September 2010 a press release declared that it was ineffective for Systematic Lupus Erythematosus (SLE). As Lupus Nephritis (LN) is caused due to SLE, it did not meet the primary endpoints for lupus nephritis either. Rituximab is used as an off-label drug for lupus nephritis, and was expected to be a promising drug as it was undergoing trials for the disease, but a press release published by Genentech and Biogen on March 13, 2009 said that its Phase III LUNAR study of Rituxan (rituximab) plus mycophenolate mofetil and corticosteroids in patients with lupus nephritis did not meet its primary endpoint of significantly reducing disease activity at 52 weeks. Hence, new products are needed to meet the unmet needs of the market, and will provide physicians with a better choice in treating lupus nephritis. In summary, the global lupus nephritis therapeutics market is heading towards a weak competitive landscape.

For Sample Pages, please click or add the below link to your browser:
http://globaldata.com/reportstore/RequestSamplePages.aspx...

GlobalData found that the current competition in the lupus nephritis market is weak. The market is devoid of any treatments being approved by the FDA or the EMEA for the treatment of lupus nephritis. This is due to the poor understanding of the pathophysiology of the disease and also the niche symptoms the disease possesses, which often make the disease go unnoticed. The off-label usage of drugs like immunosuppressants and corticosteroids in general is aimed at managing conditions that contribute to lupus nephritis. Hence, high unmet need exists in the lupus nephritis market.

GlobalData, the industry analysis specialist, has released its new report, “Lupus Nephritis therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global lupus nephritis therapeutics market. The report identifies the key trends shaping and driving the global lupus nephritis therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global lupus nephritis therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://globaldata.com/reportstore/Report.aspx?ID=Lupus-Ne...

Visit our report store: http://www.globaldata.com

For more details contact:
pressreleases@globaldata.com            
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.